A Prospective, Open, Single-Arm, Multicenter Phase II Clinical Trial to Evaluate the Progression Free Survival and Safety in Patients With Advanced Colorectal Carcinoma Treated With AMT2003
The study will include patients with advanced colorectal carcinoma that is refractory to
standard therapy or for which no effective standard therapy exists. Eligible patients must
have had at least second-line chemotherapy.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression free survival;at 18 weeks after registration
Joachim Drevs, PD Dr. med.
Clinic Sanafontis, Freiburg
Germany: Federal Institute for Drugs and Medical Devices
AMT/P2GI/001 Part III